芬通过刺激CICR和CaV来增强心脏收缩能力1.2
1Departamento de Bioquímica, Cinvestav-IPN, AP 14-740, México City, 07000, México.
Biochemical and biophysical research communications
|October 3, 2023
概括
芬 (AKF-PD) 通过增加通道开放概率,显著提高心脏肌细胞收缩性. 这种新型化合物可能为心脏病提供治疗潜力.
科学领域:
- 心血管生理学心血管生理学
- 药理学 药理学是指药理学的学科.
- 分子心脏病学分子心脏病学
背景情况:
- 芬 (AKF-PD) 是一种已知的抗纤维素和抗炎药物,在各种器官损伤模型中具有有效性.
- AKF-PD对心脏肌细胞功能和潜在的分子机制的特定影响仍然在很大程度上未被探索.
- 了解AKF-PD对心脏细胞的影响对于评估其治疗心脏病的潜力至关重要.
研究的目的:
- 为了研究黄 (AKF-PD) 对成年大鼠心脏肌细胞的功能影响.
- 阐明AKF-PD对肌细胞收缩性,细胞内处理和离子通道活性的影响.
- 确定AKF-PD作为治疗心脏病的治疗剂的潜力.
主要方法:
- 培养成年大鼠心肌细胞用AKF-PD (500μM) 或对照条件进行治疗.
- 评估了细胞收缩性,细胞内Ca2+过渡物 (电气引起和咖啡因引起) 和电压关闭的Ca2+通道 (CaV1.2) 活性.
- 关键参数包括细胞缩短,收缩/放松速率,Ca2+过渡物,CaV1.2导电量 (Gmax) 和Na/Ca交换器活性被量化.
主要成果:
- AKF-PD显著增加了肌细胞缩短,收缩和放松率,约100%左右.
- 该化合物增强了电气唤起的Ca2+过渡体,表明Ca2+诱导的Ca2+释放 (CICR) 的刺激,而不会改变质网膜的Ca2+负荷.
- AKF-PD增加了CaV1.2电流 (ICa) 大小和最大导电量 (Gmax) ~50%,可能是通过增加通道开放概率 (Po),并可能抑制了Na/Ca交换器.
结论:
- 芬 (AKF-PD) 提高了CaV1.2通道的开放概率,从而提高了ICa,CICR和心肌细胞收缩性.
- AKF-PD对心肌细胞表现出一种新的促收缩作用,与其已知的抗纤维素特性不同.
- 这些发现表明,AKF-PD是进一步研究心脏病模型的有希望的候选人.
相关概念视频
Heart Failure Drugs: Inotropic Agents
611
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
611
Heart Failure Drugs: β-Blockers
357
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
357
Heart Failure Drugs: Diuretics
412
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
412
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
553
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
553
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
868
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
868


